EGFR and lung adenocarcinoma: To understand the impact of PIK3CA mutation on clinical characteristics of advanced lung adenocarcinoma and the treatment response of EGFR TKIs, we examined PIK3CA and EGFR mutations from lung adenocarcinoma patients, and analyzed their clinical treatment outcomes.